as 11-15-2024 4:00pm EST
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
Founded: | 2016 | Country: | United States |
Employees: | N/A | City: | AUSTIN |
Market Cap: | 59.7M | IPO Year: | 2020 |
Target Price: | $2.00 | AVG Volume (30 days): | 357.1K |
Analyst Decision: | Hold | Number of Analysts: | 3 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.52 | EPS Growth: | N/A |
52 Week Low/High: | $1.07 - $11.76 | Next Earning Date: | 11-14-2024 |
Revenue: | $6,435,000 | Revenue Growth: | 382.75% |
Revenue Growth (this year): | 115.09% | Revenue Growth (next year): | N/A |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Schreiber Taylor | STTK | Chief Executive Officer | Oct 7 '24 | Buy | $1.21 | 36,500 | $44,219.75 | 71,002 |
STTK Breaking Stock News: Dive into STTK Ticker-Specific Updates for Smart Investing
Simply Wall St.
a day ago
TipRanks
2 days ago
GlobeNewswire
3 days ago
Zacks
24 days ago
Argus Research
a month ago
Zacks
a month ago
MT Newswires
2 months ago
Pharmaceutical Technology
2 months ago
The information presented on this page, "STTK Shattuck Labs Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.